New frontiers of ophthalmology - Part II

Article

In the second of a two-part article Drs Lombardi and Belilli present the results of a patient suffering with a wet maculopathy affecting both eyes.

In October 2005, further to an examination, she was diagnosed with maculopathy of the left eye and subsequently underwent eight sessions of photodynamic therapy, with the tragic outcome of the vision in her left eye being reduced from 8/10 to finger count at 10 cm.

When Professor Lombardi's team first saw her back on 5th March, 2007 they observed the following clinical picture:

Treatment with autologous stem cells was performed on April 25th 2008. The patient was administered approx. 4 ml of stem cells in one deep retrobulbar injection.

Outcome

This was followed by a visus improvement of the right eye with a -1.5 -0.5 correction (110°)→ 10/10 and of the left eye with a -1.5 -1.5 correction (170°)→ 1/50 wide.

The Macula-Threshold test is particularly important as regards photosensibility indexes directly related to the "bio-energetic index" of retinal photo-receptors, since it shows two things:

2. when the value was below 28-30, at the level of the visual field, the photo-receptor involved was probably 'Bio-energised' through 'Bio-resonance,' thereby increasing its absolute sensibility levels.

Conclusions

"We are putting all our efforts in this new frontier with pride and satisfaction, as wehave done with other breakthroughs in ophthalmology in the past and we are now starting to reap the fruit of this work.

"Day after day we have been perfecting both the preparatory stage and the stem cell treatment itself. So, we will return to this issue with new articles and updates on ongoing treatments and results."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.